Details of the Drug

General Information of Drug (ID: DMHPRWG)

Drug Name
Exjade
Synonyms Deferasirox
Indication
Disease Entry ICD 11 Status REF
Iron overload disease 5C64.10 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 373.4
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 70% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.84 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 - 16 hours [4]
Metabolism
The drug is metabolized via the hepatic [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.004% [4]
Vd
The volume of distribution (Vd) of drug is 14.37 +/- 2.69 L [5]
Chemical Identifiers
Formula
C21H15N3O4
IUPAC Name
4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
Canonical SMILES
C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
InChI
InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
InChIKey
BOFQWVMAQOTZIW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
214348
ChEBI ID
CHEBI:49005
CAS Number
201530-41-8
TTD ID
D0Q5UQ
VARIDT ID
DR00452
ACDINA ID
D00172

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Iron (Fe) TTUDR0C NOUNIPROTAC Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Exjade (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Exjade and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [13]
Midostaurin DMI6E0R Moderate Increased metabolism of Exjade caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Arn-509 DMT81LZ Moderate Increased metabolism of Exjade caused by Arn-509 mediated induction of UGT. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Exjade caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Oliceridine DM6MDCF Moderate Increased metabolism of Exjade caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [17]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Exjade and Inotersen. Amyloidosis [5D00] [15]
Ivabradine DM0L594 Moderate Increased metabolism of Exjade caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [15]
Dronedarone DMA8FS5 Moderate Increased metabolism of Exjade caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Exjade and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Exjade caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [15]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Exjade caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Cariprazine DMJYDVK Moderate Increased metabolism of Exjade caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [15]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Exjade and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [21]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Exjade caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
LY2835219 DM93VBZ Moderate Increased metabolism of Exjade caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Increased metabolism of Exjade caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Palbociclib DMD7L94 Moderate Increased metabolism of Exjade caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Alpelisib DMEXMYK Moderate Increased metabolism of Exjade caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Exjade caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Exjade caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Macitentan DMP79A1 Moderate Increased metabolism of Exjade caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [26]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Exjade and Iodipamide. Cholelithiasis [DC11] [27]
PF-04449913 DMSB068 Moderate Increased metabolism of Exjade caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [28]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Exjade and Levomilnacipran. Chronic pain [MG30] [29]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Exjade caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [30]
Ulipristal DMBNI20 Moderate Increased metabolism of Exjade caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [15]
Osilodrostat DMIJC9X Moderate Increased metabolism of Exjade caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [31]
Ivacaftor DMZC1HS Moderate Increased metabolism of Exjade caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Exjade and Vilazodone. Depression [6A70-6A7Z] [29]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Exjade and Vortioxetine. Depression [6A70-6A7Z] [29]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Exjade and Milnacipran. Depression [6A70-6A7Z] [29]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Exjade and Desvenlafaxine. Depression [6A70-6A7Z] [29]
OPC-34712 DMHG57U Moderate Decreased metabolism of Exjade caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [20]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Exjade caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [20]
Stiripentol DMMSDOY Moderate Decreased metabolism of Exjade caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Exjade and Cannabidiol. Epileptic encephalopathy [8A62] [15]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Exjade caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [33]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Exjade caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [20]
Mirabegron DMS1GYT Minor Increased metabolism of Exjade caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [34]
Ripretinib DM958QB Moderate Increased metabolism of Exjade caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [13]
Boceprevir DMBSHMF Moderate Increased metabolism of Exjade caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Telaprevir DMMRV29 Moderate Increased metabolism of Exjade caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
177Lu-DOTATATE DMT8GVU Major Increased risk of nephrotoxicity by the combination of Exjade and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [20]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Exjade and Brentuximab vedotin. Hodgkin lymphoma [2B30] [36]
MK-1439 DM215WE Moderate Increased metabolism of Exjade caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fostemsavir DM50ILT Minor Increased metabolism of Exjade caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Dolutegravir DMCZGRE Minor Increased metabolism of Exjade caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Etravirine DMGV8QU Moderate Decreased metabolism of Exjade caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Exjade caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Maraviroc DMTL94F Moderate Decreased metabolism of Exjade caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Exjade and Mipomersen. Hyper-lipoproteinaemia [5C80] [40]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Exjade and Teriflunomide. Hyper-lipoproteinaemia [5C80] [41]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Exjade and BMS-201038. Hyper-lipoproteinaemia [5C80] [42]
Levamlodipine DM92S6N Moderate Decreased metabolism of Exjade caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [20]
Tolvaptan DMIWFRL Moderate Increased metabolism of Exjade caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [15]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Exjade caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [15]
Givosiran DM5PFIJ Major Increased risk of nephrotoxicity by the combination of Exjade and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [20]
Suvorexant DM0E6S3 Moderate Increased metabolism of Exjade caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [43]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Exjade caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [44]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Exjade caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Naloxegol DML0B41 Moderate Increased metabolism of Exjade caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [45]
Pemigatinib DM819JF Moderate Increased metabolism of Exjade caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [15]
Crizotinib DM4F29C Moderate Increased metabolism of Exjade caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [46]
Brigatinib DM7W94S Moderate Increased metabolism of Exjade caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [13]
Ceritinib DMB920Z Moderate Decreased metabolism of Exjade caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Exjade caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [47]
PF-06463922 DMKM7EW Moderate Increased metabolism of Exjade caused by PF-06463922 mediated induction of UGT. Lung cancer [2C25] [13]
Osimertinib DMRJLAT Moderate Increased metabolism of Exjade caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [48]
Capmatinib DMYCXKL Moderate Increased metabolism of Exjade caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Moderate Increased metabolism of Exjade caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [20]
Artemether DM48QOT Moderate Decreased metabolism of Exjade caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [20]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Exjade caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [13]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Exjade and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [50]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Exjade and Idelalisib. Mature B-cell leukaemia [2A82] [51]
GDC-0199 DMH0QKA Moderate Increased metabolism of Exjade caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
Moxetumomab pasudotox DMN63DZ Major Increased risk of nephrotoxicity by the combination of Exjade and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [20]
IPI-145 DMWA24P Moderate Increased metabolism of Exjade caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [53]
Vemurafenib DM62UG5 Moderate Increased metabolism of Exjade caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [54]
Selumetinib DMC7W6R Moderate Increased metabolism of Exjade caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [55]
Gallium nitrate DMF9O6B Major Increased risk of nephrotoxicity by the combination of Exjade and Gallium nitrate. Mineral excesses [5B91] [20]
Flibanserin DM70DTN Moderate Increased metabolism of Exjade caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [56]
Panobinostat DM58WKG Moderate Increased metabolism of Exjade caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [57]
Romidepsin DMT5GNL Moderate Decreased metabolism of Exjade caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [20]
Rolapitant DM8XP26 Moderate Increased metabolism of Exjade caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [58]
Entrectinib DMMPTLH Moderate Increased metabolism of Exjade caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [59]
Olaparib DM8QB1D Moderate Increased metabolism of Exjade caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [13]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Exjade caused by Rucaparib mediated inhibition of UGT. Ovarian cancer [2C73] [60]
Pimavanserin DMR7IVC Moderate Increased metabolism of Exjade caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [61]
Macimorelin DMQYJIR Moderate Increased metabolism of Exjade caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [62]
Lefamulin DME6G97 Moderate Increased metabolism of Exjade caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [63]
Choline salicylate DM8P137 Major Increased risk of nephrotoxicity by the combination of Exjade and Choline salicylate. Postoperative inflammation [1A00-CA43] [20]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Exjade caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [64]
Enzalutamide DMGL19D Moderate Decreased metabolism of Exjade caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [65]
Darolutamide DMV7YFT Moderate Increased metabolism of Exjade caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [66]
Silodosin DMJSBT6 Moderate Increased metabolism of Exjade caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [13]
Apremilast DMTWS9E Moderate Decreased metabolism of Exjade caused by Apremilast mediated inhibition of CYP450 enzyme. Psoriasis [EA90] [20]
Selexipag DMAHSU0 Moderate Decreased metabolism of Exjade caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [13]
Ambrisentan DMD1QXW Moderate Decreased metabolism of Exjade caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [20]
Riociguat DMXBLMP Moderate Increased metabolism of Exjade caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [67]
Axitinib DMGVH6N Moderate Increased metabolism of Exjade caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [68]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Exjade and Temsirolimus. Renal cell carcinoma [2C90] [20]
Upadacitinib DM32B5U Moderate Decreased metabolism of Exjade caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [20]
Tofacitinib DMBS370 Moderate Decreased metabolism of Exjade caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [20]
Asenapine DMSQZE2 Moderate Decreased metabolism of Exjade caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [69]
Avanafil DM75CXN Moderate Increased metabolism of Exjade caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [70]
LDE225 DMM9F25 Moderate Increased metabolism of Exjade caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [71]
Larotrectinib DM26CQR Moderate Increased metabolism of Exjade caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Exjade and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [15]
Armodafinil DMGB035 Moderate Increased metabolism of Exjade caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [72]
LEE011 DMMX75K Moderate Increased metabolism of Exjade caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Telavancin DM58VQX Major Increased risk of nephrotoxicity by the combination of Exjade and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [20]
Fostamatinib DM6AUHV Moderate Increased metabolism of Exjade caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [73]
Saxagliptin DMGXENV Moderate Decreased metabolism of Exjade caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [20]
Linagliptin DMWFJTR Moderate Decreased metabolism of Exjade caused by Linagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [20]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Exjade and Plazomicin. Urinary tract infection [GC08] [20]
Elagolix DMB2C0E Moderate Increased metabolism of Exjade caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [74]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Exjade and Valganciclovir. Virus infection [1A24-1D9Z] [13]
⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Deferasirox 125 mg tablet 125 mg Tablet for Oral Suspension Oral
Deferasirox 180 mg tablet 180 mg Oral Tablet Oral
Deferasirox 250 mg tablet 250 mg Tablet for Oral Suspension Oral
Deferasirox 360 mg tablet 360 mg Oral Tablet Oral
Deferasirox 500 mg tablet 500 mg Tablet for Oral Suspension Oral
Deferasirox 90 mg tablet 90 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
9 A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
10 ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
11 Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.
12 Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
18 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
21 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
22 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
23 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
24 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
26 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
27 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
28 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
29 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
30 Product Information. Desferal (deferoxamine). Novartis Pharmaceuticals, East Hanover, NJ.
31 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
32 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
33 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
34 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
35 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
36 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
37 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
38 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
39 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
40 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41 Canadian Pharmacists Association.
42 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
43 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
44 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
45 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46 Cerner Multum, Inc. "Canadian Product Information.".
47 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
48 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
50 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
51 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
52 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
53 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
54 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
55 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
56 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
57 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
59 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
60 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
61 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
62 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
63 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
65 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
66 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
67 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
68 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
69 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
70 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
71 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
73 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
74 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.